INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
Dana–Farber Cancer Institute
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (143)
2024
-
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica, Vol. 109, Núm. 3, pp. 895-905
-
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study
European Journal of Haematology, Vol. 112, Núm. 3, pp. 402-411
2023
-
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 9, pp. 687-696
-
Generation of mouse models carrying B cell restricted single or multiplexed loss-of-function mutations through CRISPR-Cas9 gene editing
STAR Protocols, Vol. 4, Núm. 4
-
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia
Blood Advances
-
In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities
Blood cancer discovery, Vol. 4, Núm. 2, pp. 150-169
-
Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models
Blood Advances, Vol. 7, Núm. 16, pp. 4514-4517
-
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
The New England journal of medicine, Vol. 389, Núm. 11, pp. 1009-1022
-
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Blood cancer journal, Vol. 13, Núm. 1, pp. 116
-
New developments in the diagnosis and characterization of Waldenström’s macroglobulinemia
Expert Review of Hematology, Vol. 16, Núm. 11, pp. 835-847
-
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
British Journal of Cancer, Vol. 128, Núm. 12, pp. 2283-2294
-
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
Blood, Vol. 142, Núm. 2, pp. 141-145
-
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia
Future Oncology, Vol. 19, Núm. 5, pp. 345-353
-
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria
Seminars in Hematology
-
Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
Seminars in Hematology
-
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 33, pp. 5099-5106
2022
-
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
The Lancet. Haematology, Vol. 9, Núm. 6, pp. e403-e414
-
Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (Clinical Lymphoma, Myeloma and Leukemia (2021) 21(S2) (S1–S189), (S2152265021X00122))
Clinical Lymphoma, Myeloma and Leukemia
-
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study
American Journal of Hematology
-
Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment
Frontiers in Oncology, Vol. 12